Almirall, S.A. (ALM.MC) and Forest Laboratories, Inc. (NYSE: FRX) announced positive top-line results of ATTAIN, a six month double-blind placebo-controlled pivotal Phase III study comparing the efficacy and safety of inhaled aclidinium bromide 200??g and 400??g twice daily (BID) versus placebo, in 828 patients with moderate to severe COPD.

Aclidinium 200?µg and 400?µg produced statistically significant increases from baseline in morning pre-dose (trough) FEV1 versus placebo at week 24 (99mL and 128mL, respectively; p